Auro Laboratories Limited revenue rises 58%, profit up 64%

Auro Laboratories Limited reported revenue from operations of Rs 13.94 crore for the quarter ended September 30, 2026, up 58% from Rs 8.84 crore a year earlier, while profit after tax rose 64% to Rs 1.17 crore. The standalone, unaudited results were approved by the board on November 13, 2026.

What did Auro Laboratories report for the September 2026 quarter?

Auro Laboratories reported total income of Rs 14.18 crore for the quarter ended September 30, 2026, compared with Rs 9.81 crore in the quarter ended September 30, 2025. Revenue from operations contributed Rs 13.94 crore to the latest-quarter total, while other income was Rs 23.61 lakh. The results were reviewed by the audit committee and approved by the board on November 13, 2026.

Profit before tax was Rs 1.87 crore in the September 2026 quarter, compared with Rs 1.72 crore a year earlier. Deferred tax expense declined to Rs 69.18 lakh from Rs 1.00 crore, while the statement showed no current tax expense in either quarter. Consequently, profit after tax increased by Rs 45.78 lakh to Rs 1.17 crore from Rs 71.57 lakh.

Total comprehensive income was Rs 1.17 crore in the latest quarter, compared with Rs 38.05 lakh in the September 2025 quarter. The difference between comprehensive income and profit after tax reflected other comprehensive income after tax of negative Rs 17,000 in September 2026, versus negative Rs 33.52 lakh a year earlier. The results showed no profit or loss from discontinuing operations in either period.

How did Auro Laboratories’ revenue change from earlier periods?

Auro Laboratories’ operating revenue rose 57.8% year on year to Rs 13.94 crore from Rs 8.84 crore and increased from Rs 8.77 crore in the quarter ended June 30, 2026. The September-quarter revenue was therefore higher than both comparative quarters in the standalone statement. Revenue from operations increased by Rs 5.10 crore from the September 2025 quarter.

Auro Laboratories’ total-income growth was moderated by lower other income. Other income was Rs 23.61 lakh in the September 2026 quarter, down from Rs 97.58 lakh a year earlier, although it was above Rs 10.83 lakh in the June 2026 quarter. Total income consequently increased by Rs 4.36 crore year on year, less than the Rs 5.10 crore increase in operating revenue.

For the half year ended September 30, 2026, revenue from operations was Rs 22.71 crore, compared with Rs 11.61 crore in the corresponding 2025 half year. Total income rose to Rs 23.05 crore from Rs 13.00 crore, despite other income declining to Rs 34.44 lakh from Rs 1.39 crore. The half-year figures combine the quarters ended June 30 and September 30, 2026.

Which costs increased in Auro Laboratories’ September quarter?

Auro Laboratories reported total expenses of Rs 12.31 crore for the September 2026 quarter, compared with Rs 8.09 crore a year earlier and Rs 7.75 crore in the June 2026 quarter. Expenses increased by Rs 4.22 crore year on year, compared with a Rs 5.10 crore rise in revenue from operations. The filing provides no management explanation attributing these movements to a specific event.

Finance cost rose to Rs 1.39 crore from Rs 96.23 lakh in the September 2025 quarter and Rs 1.37 crore in the preceding quarter. Depreciation and amortisation increased to Rs 93.20 lakh from Rs 65.08 lakh a year earlier, after being Rs 91.36 lakh in June 2026. These two expense lines were both higher than in each comparative quarter shown in the results.

Employee benefits expense was Rs 1.50 crore, compared with Rs 1.45 crore in September 2025 and Rs 1.26 crore in June 2026. Other expenses were Rs 3.15 crore, versus Rs 3.06 crore and Rs 2.48 crore, respectively. Changes in inventories of finished goods, work in progress and stock in trade were negative Rs 2.40 crore, compared with negative Rs 4.20 crore a year earlier.

What do Auro Laboratories’ half-year profit and earnings per share show?

Auro Laboratories reported half-year profit after tax of Rs 2.22 crore for the period ended September 30, 2026, against Rs 61.03 lakh in the corresponding 2025 period. Profit before tax was Rs 3.00 crore, compared with Rs 1.61 crore a year earlier. Deferred tax expense was Rs 77.67 lakh in the 2026 half year, down from Rs 1.00 crore in the prior-year half year.

Basic and diluted earnings per share were Rs 3.56 for the half year ended September 30, 2026, compared with Rs 0.98 for the corresponding period in 2025. For the September 2026 quarter, basic and diluted earnings per share were Rs 1.88, against Rs 1.15 a year earlier. The company stated that the equity shares have a face value of Rs 10 each.

Paid-up equity share capital was Rs 6.23 crore at September 30, 2026, unchanged from June 30, 2026 and September 30, 2025. For the year ended March 31, 2026, Auro Laboratories reported revenue from operations of Rs 30.74 crore and profit after tax of Rs 3.53 crore. The latest half-year revenue equalled about 74% of the preceding full-year revenue, which is a comparison rather than an outlook for the remaining six months.

Does Auro Laboratories disclose pharmaceutical segment details?

Auro Laboratories says it operates in a single pharmaceuticals segment and therefore provides no additional operating-segment disclosures under Indian Accounting Standard 108. The Rs 13.94 crore of September-quarter revenue is not split by product line, geography or pharmaceutical subsegment. The statement is prepared under Indian Accounting Standards, including Indian Accounting Standard 34 for interim reporting.

Auro Laboratories described the September 2026 figures as standalone and unaudited, while its statutory auditors conducted a limited review under Regulation 33 of the Securities and Exchange Board of India’s Listing Obligations and Disclosure Requirements Regulations, 2015. The annual figures for the year ended March 31, 2026 were marked audited. The company also said earlier-period figures had been regrouped, reworked or rearranged where necessary for comparability.

The board meeting began at 4:00 p.m. and concluded at 5:00 p.m. on November 13, 2026. Auro Laboratories said the results would be published in newspapers in due course under Regulation 47(1)(b). The announcement did not disclose a revenue target, profit forecast, capacity plan, dividend proposal or product-specific guidance.

Conclusion

Auro Laboratories’ September 2026 result combined a 58% increase in operating revenue to Rs 13.94 crore with a 64% rise in profit after tax to Rs 1.17 crore. Total expenses rose to Rs 12.31 crore, including finance cost of Rs 1.39 crore and depreciation and amortisation of Rs 93.20 lakh, while lower other income limited growth in total income relative to revenue.

The disclosed next step is publication of the approved results in newspapers in due course. Subsequent filings can show whether operating revenue, finance cost and deferred tax expense move from the September-quarter levels of Rs 13.94 crore, Rs 1.39 crore and Rs 69.18 lakh, respectively.